CL2021000892A1 - Avexitida para el tratamiento de la hipoglucemia hiperinsulinémica - Google Patents

Avexitida para el tratamiento de la hipoglucemia hiperinsulinémica

Info

Publication number
CL2021000892A1
CL2021000892A1 CL2021000892A CL2021000892A CL2021000892A1 CL 2021000892 A1 CL2021000892 A1 CL 2021000892A1 CL 2021000892 A CL2021000892 A CL 2021000892A CL 2021000892 A CL2021000892 A CL 2021000892A CL 2021000892 A1 CL2021000892 A1 CL 2021000892A1
Authority
CL
Chile
Prior art keywords
avexitide
treatment
hyperinsulinemic
hypoglycaemia
hyperinsulinemic hypoglycaemia
Prior art date
Application number
CL2021000892A
Other languages
English (en)
Spanish (es)
Inventor
Colleen M Craig
Lisa Porter
Original Assignee
Eiger Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiger Biopharmaceuticals Inc filed Critical Eiger Biopharmaceuticals Inc
Publication of CL2021000892A1 publication Critical patent/CL2021000892A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2021000892A 2018-10-15 2021-04-12 Avexitida para el tratamiento de la hipoglucemia hiperinsulinémica CL2021000892A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862745915P 2018-10-15 2018-10-15
US201862746229P 2018-10-16 2018-10-16
US201962823493P 2019-03-25 2019-03-25

Publications (1)

Publication Number Publication Date
CL2021000892A1 true CL2021000892A1 (es) 2021-11-12

Family

ID=70283142

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000892A CL2021000892A1 (es) 2018-10-15 2021-04-12 Avexitida para el tratamiento de la hipoglucemia hiperinsulinémica

Country Status (10)

Country Link
US (1) US20210338780A1 (enExample)
EP (2) EP3867266A4 (enExample)
JP (2) JP2022513351A (enExample)
CN (1) CN112867730A (enExample)
AU (2) AU2019359807B2 (enExample)
BR (1) BR112021006968A2 (enExample)
CA (1) CA3115527A1 (enExample)
CL (1) CL2021000892A1 (enExample)
IL (2) IL314504A (enExample)
WO (1) WO2020081534A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3115527A1 (en) * 2018-10-15 2020-04-23 Eiger Biopharmaceuticals, Inc. Avexitide for the treatment of hyperinsulinemic hypoglycemia
US20240307501A1 (en) 2021-06-21 2024-09-19 Eiger Biopharmaceuticals, Inc. Treatment of congenital hyperinsulinism with avexitide
WO2024220962A1 (en) * 2023-04-21 2024-10-24 The Board Of Trustees Of The Leland Stanford Junior University Glp-1r antagonism to improve nutrition following gastrointestinal surgery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2013120022A2 (en) * 2012-02-08 2013-08-15 Seneb Biosciences, Inc. Treatment of hypoglycemia
WO2015022420A1 (en) * 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
SMT202100668T1 (it) * 2015-05-22 2022-01-10 Univ Leland Stanford Junior Trattamento dell'ipoglicemia post-bariatrica con antagonisti del glp-1
US10653753B2 (en) * 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
JP7584894B2 (ja) * 2016-11-21 2024-11-18 アイガー・バイオファーマシューティカルズ・インコーポレイテッド エキセンディン（９－３９）の緩衝製剤
CA3115527A1 (en) * 2018-10-15 2020-04-23 Eiger Biopharmaceuticals, Inc. Avexitide for the treatment of hyperinsulinemic hypoglycemia

Also Published As

Publication number Publication date
AU2019359807A1 (en) 2021-05-13
EP4233842A2 (en) 2023-08-30
WO2020081534A1 (en) 2020-04-23
IL314504A (en) 2024-09-01
AU2025208421A1 (en) 2025-08-14
CN112867730A (zh) 2021-05-28
US20210338780A1 (en) 2021-11-04
CA3115527A1 (en) 2020-04-23
EP4233842A3 (en) 2023-10-25
EP3867266A1 (en) 2021-08-25
AU2019359807B2 (en) 2025-04-24
JP2025000798A (ja) 2025-01-07
IL282059A (en) 2021-05-31
BR112021006968A2 (pt) 2021-07-27
JP2022513351A (ja) 2022-02-07
EP3867266A4 (en) 2022-07-13

Similar Documents

Publication Publication Date Title
MX2024007358A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso.
CO2017011197A2 (es) Terapia de combinación fgfr/pd-1 para el tratamiento del cancer
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
MX2016016115A (es) Metodo para tratar cancer usando una combinacion de inhibidores de chk1 y relacionado con atm y rad3 (atr).
EA201790398A1 (ru) Способы лечения заболевания печени
CO6331301A2 (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa
MX2018003331A (es) Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
DOP2025000199A (es) Agonistas heterocíclicos de glp-1
MX388380B (es) Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
DOP2021000044A (es) Moduladores de la expresión de pnpla3
AR105712A1 (es) Composiciones de insulina de rápida acción
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
MX2019001036A (es) Tratamiento y prevencion de los trastornos del sueño.
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
ES3064032T3 (en) Ophthalmological compositions comprising brimonidine and ketotifen for use in the treatment of allergies
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
CL2023000121A1 (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas
CL2021001246A1 (es) Moduladores de expresión irf5.
BR112017014914A2 (pt) terapia combinada para hipertensão pulmonar
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.
EP4233842A3 (en) Avexitide for the treatment of hyperinsulinemic hypoglycemia
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.